(Q39067316)

8 September 2017

title

Novel targets for hepatitis B virus therapy (English)

1 reference

8 September 2017

1 reference

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28052622%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

Barbara Testoni

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28052622%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

Fabien Zoulim

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28052622%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

1

Barbara Testoni

1 reference

8 September 2017

3

Fabien Zoulim

1 reference

8 September 2017

publication date

1 January 2017

1 reference

8 September 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28052622%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

volume

37 Suppl 1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28052622%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

page(s)

33-39

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28052622%20AND%20SRC:MED&resulttype=core&format=json

Infection and Cancer: The Case of Hepatitis B.

9 June 2020

cites work

1 reference

Epidemiology of viral hepatitis and hepatocellular carcinoma

21 January 2018

1 reference

Molecular biology of hepatitis B virus infection

21 January 2018

1 reference

HBV cccDNA: viral persistence reservoir and key obstacle for a cure of chronic hepatitis B.

21 January 2018

1 reference

Antiviral therapies and prospects for a cure of chronic hepatitis B.

21 January 2018

1 reference

Chronic hepatitis B: Virology, natural history, current management and a glimpse at future opportunities

21 January 2018

1 reference

Risk for hepatocellular carcinoma in the course of chronic hepatitis B virus infection and the protective effect of therapy with nucleos(t)ide analogues

21 January 2018

1 reference

Risk of hepatocellular carcinoma in chronic hepatitis B: assessment and modification with current antiviral therapy.

21 January 2018

1 reference

Hepatitis B virus resistance to nucleos(t)ide analogues.

21 January 2018

1 reference

Towards an HBV cure: state-of-the-art and unresolved questions--report of the ANRS workshop on HBV cure.

21 January 2018

1 reference

Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus

21 January 2018

1 reference

Strategies to inhibit entry of HBV and HDV into hepatocytes.

21 January 2018

1 reference

Humanized chimeric uPA mouse model for the study of hepatitis B and D virus interactions and preclinical drug evaluation.

21 January 2018

1 reference

Involvement of the host DNA-repair enzyme TDP2 in formation of the covalently closed circular DNA persistence reservoir of hepatitis B viruses

21 January 2018

1 reference

Does Tyrosyl DNA Phosphodiesterase-2 Play a Role in Hepatitis B Virus Genome Repair?

21 January 2018

1 reference

Identification of disubstituted sulfonamide compounds as specific inhibitors of hepatitis B virus covalently closed circular DNA formation

21 January 2018

1 reference

Specific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA.

21 January 2018

1 reference

Interferon-γ and Tumor Necrosis Factor-α Produced by T Cells Reduce the HBV Persistence Form, cccDNA, Without Cytolysis.

21 January 2018

1 reference

Targeting Hepatitis B Virus With CRISPR/Cas9.

21 January 2018

1 reference

Targeting hepatitis B virus cccDNA using CRISPR/Cas9.

21 January 2018

1 reference

Complete Spectrum of CRISPR/Cas9-induced Mutations on HBV cccDNA.

21 January 2018

1 reference

IFN-α inhibits HBV transcription and replication in cell culture and in humanized mice by targeting the epigenetic regulation of the nuclear cccDNA minichromosome

21 January 2018

1 reference

Mapping of histone modifications in episomal HBV cccDNA uncovers an unusual chromatin organization amenable to epigenetic manipulation

21 January 2018

1 reference

Hepatitis B virus X protein is essential to initiate and maintain virus replication after infection.

21 January 2018

1 reference

Hepatitis B virus X protein identifies the Smc5/6 complex as a host restriction factor.

21 January 2018

1 reference

Hepatitis B Virus X Protein Promotes Degradation of SMC5/6 to Enhance HBV Replication

21 January 2018

1 reference

Synthetic RNAi triggers and their use in chronic hepatitis B therapies with curative intent.

21 January 2018

1 reference

Core protein: A pleiotropic keystone in the HBV lifecycle

21 January 2018

1 reference

The main hepatitis B virus (HBV) mutants resistant to nucleoside analogs are susceptible in vitro to non-nucleoside inhibitors of HBV replication

21 January 2018

1 reference

Hepatitis B virus reverse transcriptase - Target of current antiviral therapy and future drug development

21 January 2018

1 reference

Implications of efficient hepatic delivery by tenofovir alafenamide (GS-7340) for hepatitis B virus therapy

21 January 2018

1 reference

Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.

21 January 2018

1 reference

The hepatitis B virus ribonuclease H as a drug target

21 January 2018

1 reference

Hydroxylated tropolones inhibit hepatitis B virus replication by blocking viral ribonuclease H activity

21 January 2018

1 reference

Safety and Efficacy of Nucleic Acid Polymers in Monotherapy and Combined with Immunotherapy in Treatment-Naive Bangladeshi Patients with HBeAg+ Chronic Hepatitis B Infection

21 January 2018

1 reference

HBV and the immune response

21 January 2018

1 reference

The role of natural killer cells and CD8(+) T cells in hepatitis B virus infection

21 January 2018

1 reference

Dissecting the divergent effects of interferon-alpha on immune cells: time to rethink combination therapy in chronic hepatitis B?

21 January 2018

1 reference

Immune-modulators to combat hepatitis B virus infection: From IFN-α to novel investigational immunotherapeutic strategies

21 January 2018

1 reference

BDCA3(+)CLEC9A(+) human dendritic cell function and development

21 January 2018

1 reference

Dendritic cell maturation: functional specialization through signaling specificity and transcriptional programming

21 January 2018

1 reference

GS-9620, an oral agonist of Toll-like receptor-7, induces prolonged suppression of hepatitis B virus in chronically infected chimpanzees

21 January 2018

1 reference

Sustained efficacy and seroconversion with the Toll-like receptor 7 agonist GS-9620 in the Woodchuck model of chronic hepatitis B

21 January 2018

1 reference

The oral toll-like receptor-7 agonist GS-9620 in patients with chronic hepatitis B virus infection

21 January 2018

1 reference

STING agonists induce an innate antiviral immune response against hepatitis B virus

21 January 2018

1 reference

Regulation of Toll-like receptor-2 expression in chronic hepatitis B by the precore protein

21 January 2018

1 reference

Role of Toll-like receptor 2 in the immune response against hepadnaviral infection.

21 January 2018

1 reference

Interplay between hepatitis B virus and TLR2-mediated innate immune responses: can restoration of TLR2 functions be a new therapeutic option?

21 January 2018

1 reference

Eliminating hepatitis B by antagonizing cellular inhibitors of apoptosis.

21 January 2018

1 reference

Promises and Challenges of Smac Mimetics as Cancer Therapeutics

21 January 2018

1 reference

Current status of immunomodulatory therapy in chronic hepatitis B, fifty years after discovery of the virus: Search for the "magic bullet" to kill cccDNA.

21 January 2018

1 reference

T cell receptor-therapy in HBV-related hepatocellularcarcinoma

21 January 2018

1 reference

Immunotherapy of HCC metastases with autologous T cell receptor redirected T cells, targeting HBsAg in a liver transplant patient

21 January 2018

1 reference

T-cell exhaustion in chronic hepatitis B infection: current knowledge and clinical significance

21 January 2018

1 reference

Immunological aspects of antiviral therapy of chronic hepatitis B virus and hepatitis C virus infections

21 January 2018

1 reference

Metabolic regulation of hepatitis B immunopathology by myeloid-derived suppressor cells.

21 January 2018

1 reference

PD-1 blockage reverses immune dysfunction and hepatitis B viral persistence in a mouse animal model

21 January 2018

1 reference

Enhancing virus-specific immunity in vivo by combining therapeutic vaccination and PD-L1 blockade in chronic hepadnaviral infection

21 January 2018

1 reference

Expression of CD39 on FoxP3+ T regulatory cells correlates with progression of HBV infection.

21 January 2018

1 reference

Anti-HBV DNA vaccination does not prevent relapse after discontinuation of analogues in the treatment of chronic hepatitis B: a randomised trial--ANRS HB02 VAC-ADN.

21 January 2018

1 reference

Randomized phase II study of GS-4774 as a therapeutic vaccine in virally suppressed patients with chronic hepatitis B.

21 January 2018

1 reference

Therapeutic vaccines in treating chronic hepatitis B: the end of the beginning or the beginning of the end?

21 January 2018

1 reference

The immune tolerant phase of chronic HBV infection: new perspectives on an old concept

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1111/LIV.13307

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28052622%20AND%20SRC:MED&resulttype=core&format=json

release_caeevom6ura2vatsg5ityot57e

9 June 2020

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/caeevom6ura2vatsg5ityot57e

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference